A new study by radiation oncologists comparing the world’s literature on outcomes of proton beam therapy in the treatment of a variety of advanced head and neck cancers of the skull base compared to intensity modulated radiation therapy (IMRT) has found that proton beam therapy significantly improved disease free survival and tumour control when compared to IMRT.
The results appear in Lancet Oncology.
“We undertook a systematic review and meta-analysis to compare the clinical outcomes of patients treated with proton therapy with patients receiving photon IMRT,” says senior author Robert Foote, M.D., a radiation oncologist at Mayo Clinic.
“Our findings suggest that the theoretical advantages of proton beam therapy may in fact be real.”
Researchers reviewed studies of nasal cavity and paranasal sinus tumours through extensive database searches.
They included studies of patients who had no previous treatment – neither primary radiation therapy nor adjuvant radiation therapy – and patients who had recurrent disease.
Researchers collected data on overall survival, disease-free survival, and tumour control, at five years and at the patient’s longest follow-up.
They used random-effect models to pool outcomes across studies and compared event rates of combined outcomes for proton therapy and IMRT using an interaction test.
Researchers found disease free survival to be significantly higher at five years for patients receiving proton therapy than for patients receiving IMRT (72% versus 50%).
Tumour control did not differ between treatment groups at five years however tumour control was higher for patients receiving proton therapy than for IMRT at the longest follow-up (81% versus 64%).
Source: Mayo Clinic
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.